AI Article Synopsis
- Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis are severe conditions marked by skin and mucous membrane detachment and lesions, often linked to anti-epileptic drugs.
- Despite oxcarbazepine (OXC) being considered safer than carbamazepine (CBZ), a case is reported of a 6-year-old boy developing SJS following OXC treatment for benign rolandic epilepsy.
- After stopping the medication and starting topical corticosteroids, the boy's skin condition improved, highlighting the potential risks of OXC despite its perceived safety.
Article Abstract
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis are two rare but life-threatening diseases characterized by detachment of epidermis, bullous skin lesions and mucous membrane erosions. Anti-epileptic drugs are highly suspected to be the causative agents. Although carbamazepine (CBZ) is the most associated anti-epileptic drug, oxcarbazepine (OXC), which is a monohydrated derivative of CBZ, is proposed to be safer because of the different metabolism of the two drugs. Herein, we report a case of SJS induced by oxcarbazepine. A 6-year-old boy with benign rolandic epilepsy, admitted to our hospital with generalized maculopapular rash after starting oxcarbazepine. The diagnosis of SJS was made with cytotoxic skin lesions and mucous membrane involvement. After discontinuing of the drug and topical corticosteroid initiation, the lesions were improved. We report this case to attract attention to the serious side effect of this anti-epileptic drug.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451893 | PMC |
| http://dx.doi.org/10.1093/omcr/omx028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!